acute exacerbation in chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease with (acute) exacerbation
Conditions
Interventions
Intervention 1: Intervention group: This group will receive Glareta syrup. The drug's composition includes licorice, artemisia, and nepeta. The syrups are given as a tablespoon, equivalent to 10 cc, t
Sponsors
Kashan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 85 Years
Inclusion criteria
Inclusion criteria: Diagnosis of AECOPD and its associated symptoms 3. Ages between 30 and 85 who are able to take oral medication. 4. Less than 5 days since the onset of the acute complication. 5. Written and voluntary consent to participate in the study.
Exclusion criteria
Exclusion criteria: • Patients with severe shortness of breath, swallowing disorders or the possibility of aspiration of food materials • Patients with underlying lung disease such as bronchiectasis, cystic fibrosis, lung cancer, ILDs • Patients who are unable to take medication orally. • Patients with refractory hypoxemia, decreased consciousness • Patients with respiratory failure requiring mechanical ventilation, hemodynamic instability, hypercapnia, or respiratory fatigue who require admission to intensive care units. • Patients with underlying disease including: acute cardiovascular failure, uncontrolled blood pressure (SBP>140/90), uncontrolled diabetes (Hb A1C>8), advanced renal failure (Stage 3 and above), advanced liver failure (cirrhosis), BMI<04 • Pregnant or lactating women. • Immunocompromised patients including patients treated with corticosteroids, chemotherapy, malignancy, organ transplants, and HIV patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peak respiratory flow, arterial blood oxygen saturation, symptom severity, patient age, patient gender, smoking, blood pressure, respiratory rate, heart rate, body temperature, requested test, cough degree, shortness of breath degree. Timepoint: The degree of shortness of breath, peak flow rate, and cough are assessed, and blood tests are requested on days 1 and 3. The patient's vital signs are monitored every 12 hours for five days. Method of measurement: Peak respiratory flow with the help of peak flowmeter. Blood pressure with the help of a sphygmomanometer cuff, blood oxygen level and heart rate with a pulse oximeter, number of breaths per minute with counting by a nurse. Degree of shortness of breath with the mMRC questionnaire and cough questionnaire based on CSS. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNasrin Razavianzadeh
Islamic Azad University
Outcome results
None listed